GALNT15: A Potential Drug Target and Biomarker (G117248)

Target Name: GALNT15

NCBI ID: G117248

GALNT15

GALNT15: A Potential Drug Target and Biomarker

GALNT15 is a gene that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 6 and encodes for a protein known as GALNT15, which is involved in a variety of cellular processes, including cell signaling, DNA replication, and cell adhesion.

GALNT15 has been shown to be involved in several diseases and disorders, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of GALNT15 are associated with an increased risk of cancer, including breast, ovarian, and prostate cancers. Additionally, GALNT15 has been linked to a number of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Furthermore, GALNT15 has also been shown to be involved in several autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. In these conditions, the immune system attacks the body's own tissues, leading to inflammation and damage.

Despite these promising findings, more research is needed to fully understand the role of GALNT15 in disease. One of the main challenges in studying GALNT15 is its expression in different tissues and organisms, as well as its potential interactions with other genes. Additionally, there is a need for more research on the safety and efficacy of targeting GALNT15 as a drug or biomarker.

In conclusion, GALNT15 is a gene that has the potential to be a drug target or biomarker for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand its role in these conditions and to develop safe and effective treatments.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 15

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Although it displays a much weaker activity toward all substrates tested compared to GALNT2, it is able to transfer up to seven GalNAc residues to the Muc5AC peptide, suggesting that it can fill vicinal Thr/Ser residues in cooperation with other GALNT proteins. Prefers Muc1a as substrate

The "GALNT15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets